This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
The authors did not report the methods used to identify relevant data sources.
Measure of benefits used in the economic analysis
The measure of health benefit used was the quality-adjusted life-years (QALYs). Health state valuations were taken from a published randomised controlled trial (Carson et al. 2005) . The benefits were discounted at an annual rate of 3.5%.
Direct costs
The direct costs to the NHS were identified in this study. The costs of the implantation procedure and the device, inpatient stays, outpatient visits, primary care visits, time spent in nursing or rehabilitation homes, and medical costs were included. The resource use data were taken from the model detailed above, whereas the unit costs were detailed in the paper but their source was not specified. Future costs were discounted at a rate of 3.5%. No price year was reported.
Statistical analysis of costs
No statistical analysis of the cost data was undertaken.
Indirect Costs
No productivity costs were included in this study.
Currency
Euros (EUR). Pounds sterling () were converted to EUR using an exchange rate of 1 = EUR 1.47
Sensitivity analysis
A probabilistic sensitivity analysis was performed to examine the impact of uncertainty in the cost and health benefit data. The distributions of the model parameters were reported in the paper. One-way sensitivity analyses that varied the age of the model cohort, length of follow-up and the battery life of ICD implants were also undertaken.
Estimated benefits used in the economic analysis
The mean QALYs was 4.08 (95% confidence interval, CI: 3.23 to 4.82) for medical therapy alone, 6.06 (95% CI: 5.19 to 6.87) for CRT-P plus medical therapy, and 6.75 (95% CI: 5.76 to 7.72) for CRT-ICD plus medical therapy.
Cost results
The mean total lifetime cost was EUR 39,060 (95% CI: 35,510 to 43,222) for medical therapy alone, EUR 53,996 (95% CI: 50,127 to 58,092) for CRT-P plus medical therapy, and EUR 87,350 (95% CI: 82,052 to 92,521) for CRT-ICD plus medical therapy.
Synthesis of costs and benefits
In the base-case analysis, the incremental cost-utility of CRT-P plus medical therapy compared with medical therapy alone was EUR 7,538 per QALY (95% CI: 5,325 to 11,784). Comparing CRT-ICD plus medical therapy with medical
